Tremelimumab
Last Updated: 06/30/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 752 publications
Pooled analysis of 2 clinical trials of first-line chemoimmunotherapy for metastatic microsatellite stable colorectal cancer MEDITREME and METIMMOX studies.
Journal: Oncoimmunology
Published: June 20, 2026
Neoadjuvant Durvalumab ± Tremelimumab in Combination With Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Muscle-Invasive Bladder Carcinoma: Results of the Phase I/II NEMIO Study.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: May 26, 2026
An unusual presentation of Hepatocellular Carcinoma: Isolated bile duct involvement without detectable hepatic mass.
Journal: Zeitschrift fur Gastroenterologie
Published: May 11, 2026
Plain language summary of five-year overall survival update from the HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (liver cancer).
Journal: Future oncology (London, England)
Published: May 11, 2026
Interstitial lung disease associated with novel anticancer agents in non-small cell lung cancer: a pharmacovigilance analysis using the FAERS database.
Journal: Therapeutic advances in respiratory disease
Published: April 28, 2026
Autopsy-Proven Immune-Mediated Hepatitis With Rapid Liver Atrophy Despite Minimal Aminotransferase Elevation After Durvalumab Plus Tremelimumab Therapy for Hepatocellular Carcinoma: A Case Report.
Journal: Clinical case reports
Published: April 05, 2026
Favorable Response to Chemotherapy with Durvalumab plus Tremelimumab in Two Cases of KRAS G12C-Positive Pulmonary Sarcomatoid Carcinoma: A Case Report.
Journal: Internal medicine (Tokyo, Japan)
Published: March 18, 2026
Systemic immune profiling uncovers divergent mechanisms and predictive biomarkers of response to combination immunotherapies in hepatocellular carcinoma.
Journal: Journal for immunotherapy of cancer
Published: March 16, 2026
The effect of prior transarterial chemoembolization on response to immune checkpoint inhibitor treatment in patients with hepatocellular carcinoma.
Journal: Clinical and molecular hepatology
Published: March 12, 2026
An Effective Case of Radiofrequency Ablation with the Combination of Durvalumab and Tremelimumab Treatment for Hepatocellular Carcinoma: A Case Report.
Journal: Internal medicine (Tokyo, Japan)
Published: February 23, 2026
A case of immune-mediated myocarditis after durvalumab/tremelimumab treatment for unresectable hepatocellular carcinoma.
Journal: Internal medicine (Tokyo, Japan)
Published: February 23, 2026
Exceptional Response to Durvalumab and Tremelimumab in Pancreatic Acinar Cell Carcinoma With Ultramutated Phenotype Associated With a DNA Polymerase-ε Mutation.
Journal: JCO precision oncology
Published: February 13, 2026
Last Updated: 06/30/2026